RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval

RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.

Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes

Research identifies vitamin D receptors (VDR) in breast cancer tumors as a promising prognostic marker, linking VDR presence to tumor characteristics, survival outcomes, and potentially

March 26, 2024

Exscientia’s $15M milestone from Sanofi; Lilly to take Gateway Labs to China

Plus, news about TenNor Therapeutics, Gan & Lee Pharmaceuticals, Orasis and Optus Pharmaceuticals: Exscientia receives $15M milestone from Sanofi: The companies Sign up to read

October 17, 2024

Eli Lilly’s M&A Friday; Novartis’ TIGIT breakup; One big hire and one big exit; Reverse merger, shutdown and white flags; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

July 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.